New hope for arthritis sufferers: experimental drug GenSci120 enters Mid-Stage trial
NCT ID NCT07423533
First seen Feb 20, 2026 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This study tests a new drug called GenSci120 in 450 adults with moderate-to-severe rheumatoid arthritis who haven't improved with standard treatments. Participants receive either GenSci120, an existing drug (adalimumab), or a placebo for 14 weeks, followed by an extension period. The main goal is to see if GenSci120 reduces joint pain and swelling better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GenSci120 injection
What this could lead to
If successful, this could provide a new treatment option for people with rheumatoid arthritis who haven't responded well to existing drugs.
What could go wrong
This is an early Phase 2 trial, so the drug may not work better than existing treatments or could have unexpected side effects. Results are not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.